Tremelimumab and Durvalumab

Discussion Board › Forums › Clinical Trials › Tremelimumab and Durvalumab

Viewing 5 posts - 16 through 20 (of 20 total)
1 2
  • Author
    Posts
  • October 21, 2016 at 12:43 am #89443
    liverstrong
    Spectator

    Marion,

    He hasn’t had any side effects. Just dealing with the normal pain and nausea that was present prior to the trial. He had a four month chemo holiday prior to the trial. As that was coming to an end and we were waiting to get on the trial, his symptoms started to return.

    He had the TACE procedures while he was undergoing first line Gem/Cis. I think the last one was in May. They were not part of the trial. Because Sean is one of the first 10 in his cohort, he will just get the combination of the two drugs, not the ablative therapy.

    Thanks again,

    Tim and Julie

    October 20, 2016 at 10:57 pm #89441
    marions
    Moderator

    Liverstrong…..you are welcome and thank you for providing the ID No. which in turn led me to the clinicaltrials.gov identifier
    This is the trial:
    https://clinicaltrials.gov/ct2/show/NCT02821754

    How is Sean feeling? BTW: my oldest son’s name is Sean as well.

    I assume the three prior TACE treatments are considered part of the protocol, correct?

    Hugs,
    Marion

    October 20, 2016 at 10:24 pm #89442
    liverstrong
    Spectator

    Marion,

    The study number is 16-C-0135. I put the wrong one in my earlier post.

    Thanks so much for your encouragement!

    October 20, 2016 at 5:58 pm #89456
    marions
    Moderator

    Liverstrong….fantastic news. I have high hopes for Sean, he is young and has recovered well from previous treatments. You have a great team of physicians working on Sean’s behalf. So happy for you.

    I seem to have problems identifying the study, found a few, but none specifically mention cholangiocarcinoma.

    Is it possible for you to supply us with the Identifier?

    Hugs and the best of luck,
    Marion

    October 20, 2016 at 11:33 am #11618
    liverstrong
    Spectator

    Our son Sean was receiving Gem/Cis from Aug ’15 until June ’16, when scans showed some progression. He also received three TACE treatments, which seemed to help control the tumors for a time.

    We have been in communication with a group at NIH since July. Yesterday, he was able to start on a trial combining Tremelimumab and Durvalumab. The study number is 11-C-0112.

    The drugs have been used in combination for some other cancers (NSCLC and melanoma), but this is the first try on cholangio. I think there is at least one other cholangio patient in this trial.

    No side effects yet, but it’s just been hours since he received the infusions.

  • Author
    Posts
Viewing 5 posts - 16 through 20 (of 20 total)
1 2
  • The forum ‘Clinical Trials’ is closed to new topics and replies.